Ifosfamide
(Synonyms: 异环磷酰胺) 目录号 : GC16003
An alkylating agent used to treat cancer
Cas No.:3778-73-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: | In a 3-cm dish, 4 × 104 cells are seeded in 2 mL of medium. The next day, Ifosfamide is added to final concentrations from 0 to 5 mM. After six additional days the medium is removed, the cells washed with PBS, and either stained or counted[2]. |
Animal experiment: | Rats[1]Prior to mating, female rats are divided into four groups of eight: group 1, untreated negative controls; group 2, rats injected i.p. with 1 mL 0.9% NaCl; group 3, rats injected i.p. with 25 mg/kg Ifosfamide; group 4, rats injected i.p. with 50 mg/kg Ifosfamide. After injection of Ifosfamide once daily for 5 consecutive days, three females are placed in a cage with one untreated male for up to 1 week. Vaginal smears are examined daily to determine pregnancy. The first 24 h period following mating is designated day one of pregnancy if sperm are detected. The pregnant females are housed singly and observed daily for signs of toxicity and abortion. All pregnant animals are sacrificed by decapitation on day 18 of gestation. Cardiac blood (2.5 -3 mL/rat) is collected in nonheparinized test tubes, centrifuged at 3,000× g for 30 min and the serum is decanted and stored at -70°C until used for hormone assay. After blood collection, uteri and both ovaries are removed, washed in saline solution and the corpora lutea of pregnancy are counted visually, and the number of implantation sites, resorption sites and viable fetuses are counted in each uterine horn. Each fetus is removed from its umbilical cord, weighed and the crown rump (CR) length is measured. Fetuses are examined for external malformation and the placental weights are recorded. Fetuses and placentas of control and treated groups are fixed in 10% neutral buffered formalin for immunohistochemical and histological examination[1]. |
References: [1]. Helal M. Prenatal effects of transplacental exposure to ifosfamide in rats. Biotech Histochem. 2016 Jul;91(5):357-68. | |
Ifosfamide is an alkylating chemotherapeutic agent with activity against a wide range of tumors.
Ifosfamide is an alkylating chemotherapeutic agent with activity against a wide range of tumors[1]. Ifosfamide is activated by the cytochrome P450 family. Ifosfamide (0-5 mM) suppresses the viability of CYP2B1-expressing C8III-1 cells, while it is cytotoxic to the non-CYP2B1-expressing CrFK cells only at high concentration (5 mM)[2]. CYP BM3 mutants activates Ifosfamide, and Ifosfamide shows inhibitory activity against human U2OS cells[3].
Ifosfamide (50 mg/kg, i.p.) treatment before mating increases percentage of post-implantation loss and resorbs fetuses in pregnant rats. Ifosfamide also (50 mg/kg, i.p.) decreases the progesterone in the serum of pregnant rats. However, Ifosfamide causes no obvious difference with the control rats at 25 mg/kg. Ifosfamide (25, 50 mg/kg, i.p.) induces apoptosis and histological changes in the placentas and prenatal rats, most sensitive fetal organs are the brain, liver and kidney[1].
References:
[1]. Helal M. Prenatal effects of transplacental exposure to ifosfamide in rats. Biotech Histochem. 2016 Jul;91(5):357-68.
[2]. Karle P, et al. Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide. Cancer Gene Ther. 2001 Mar;8(3):220-30.
[3]. Vredenburg G, et al. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants. Toxicol Lett. 2015 Jan 5;232(1):182-92.
| Cas No. | 3778-73-2 | SDF | |
| 别名 | 异环磷酰胺 | ||
| 化学名 | N,3-bis(2-chloroethyl)-2-oxo-1,3,2λ5-oxazaphosphinan-2-amine | ||
| Canonical SMILES | C1CN(P(=O)(OC1)NCCCl)CCCl | ||
| 分子式 | C7H15Cl2N2O2P | 分子量 | 261.09 |
| 溶解度 | ≥ 13.05mg/mL in DMSO | 储存条件 | 4°C, protect from light ,unstable in solution, ready to use. |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.8301 mL | 19.1505 mL | 38.301 mL |
| 5 mM | 0.766 mL | 3.8301 mL | 7.6602 mL |
| 10 mM | 0.383 mL | 1.915 mL | 3.8301 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。